Ultragenyx Pharma (RARE) Misses Q3 EPS by 16c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.03), $0.16 worse than the analyst estimate of ($0.87).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c